Long-term, low-intensity warfarin after idiopathic venous thromboembolism

Affiliations

Comment

Daniel G Hackam. CMAJ. 2003.

. 2003 Apr 29;168(9):1160-1.

¹ St. Joseph's Hospital, and Dept. of Medicine, McMaster University, Hamilton, Ont.

No abstract available

Comment on

Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism.
Ridker PM, Goldhaber SZ, Danielson E, Rosenberg Y, Eby CS, Deitcher SR, Cushman M, Moll S, Kessler CM, Elliott CG, Paulson R, Wong T, Bauer KA, Schwartz BA, Miletich JP, Bounameaux H, Glynn RJ; PREVENT Investigators. Ridker PM, et al. N Engl J Med. 2003 Apr 10;348(15):1425-34. doi: 10.1056/NEJMoa035029. Epub 2003 Feb 24. N Engl J Med. 2003. PMID: 12601075 Clinical Trial.

1. Hyers TM, Agnelli G, Hull RD, Morris TA, Samama M, Tapson V, et al. Antithrombotic therapy for venous thromboembolic disease. Chest 2001;119(1 Suppl):176S-193S. - PubMed
1. Hirsh J, Lee AYY. How we diagnose and treat deep vein thrombosis. Blood 2002;99(9):3102-10. - PubMed
1. Bern MM, Lokich JJ, Wallach SR, Bothe A Jr., Benotti PN, Arkin CF, et al. Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. Ann Intern Med 1990;112(6):423-8. - PubMed
1. Levine M, Hirsh J, Gent M, Arnold A, Warr D, Falanga A, et al. Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 1994;343(8902):886-9. - PubMed
1. Kearon C, Ginsberg JS, Kovacs M, Anderson DR, Wells P, Julian J, et al. Low-intensity (INR 1.5-1.9) versus conventional-intensity (INR 2.0-3.0) anticoagulation for extended treatment of unprovoked VTE: a randomized double blind trial [abstract]. Blood 2002; 100: 150a.